# US 2022/0033796 A1 · Process and system for obtaining botulinum neurotoxin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033796 A1
- Document ID: US20220033796A1
- Status: Published application
- Kind: A1
- Application number: 17/505,537
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2009-07-13
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Jennifer L. Ton; Hemant A. Patel; Ronald C. Bates; Wajdie M. Ahmad
- Web page: https://patentgrep.com/patent/US20220033796A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B01D 15/361: {Ion-exchange}
- B01D 15/362: {Cation-exchange}
- B01D 15/363: {Anion-exchange}
- C07K 1/18: Ion-exchange chromatography
- C07K 14/33: from Clostridium (G)
- C12N 1/20: Bacteria; Culture media therefor
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12R 2001/145: Clostridium
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.

## Claims

### Claim 1

A substantially animal product free (APF) process utilizing chromatography for obtaining a biologically active botulinum neurotoxin, the process comprising the following steps:
(a) providing a substantially APF fermentation medium;
(b) fermenting Clostridium botulinum bacteria in the fermentation medium, and;
(c) recovering the biologically active botulinum neurotoxin from the fermentation medium by contacting the fermentation medium with an anion exchange chromatography media followed by contacting an eluent from the anion exchange chromatography medium with a cation exchange chromatography, thereby obtaining the biologically active botulinum neurotoxin from the substantially APF chromatography process.

### Claim 2 (depends on 1)

The process of claim 1, wherein the botulinum neurotoxin obtained comprises one part or less residual nucleic acid per million of the botulinum neurotoxin obtained.

### Claim 3 (depends on 1)

The process of claim 1, wherein the process is carried out in one week or less.

### Claim 4 (depends on 1)

A biologically active botulinum neurotoxin obtained by the process of claim 1.

### Claim 5

A substantially APF chromatographic process for obtaining a biologically active botulinum neurotoxin type A complex, the process comprising the following sequential steps:
(a) culturing Clostridium botulinum bacteria in a substantially APF culture medium;
(b) fermenting Clostridium botulinum bacteria from the culture medium in about 2 L to about 75 L of a substantially APF fermentation medium, wherein at least one of the culture medium and the fermentation medium includes a vegetable protein;
(c) harvesting the fermentation medium by removing cellular debris present in the fermentation medium;
(d) concentrating the harvested fermentation medium by filtration;
(e) diluting the concentrated fermentation medium by adding a buffer;
(f) a first contacting step in which the diluted harvested fermentation medium is contacted with an anion exchange media so that the biologically active botulinum neurotoxin becomes captured with the anion exchange media;
(g) eluting the captured botulinum neurotoxin from the anion exchange media to thereby obtain a first eluent;
(h) a second contacting step in which the first eluent is contacted with a cation exchange media to remove impurities from the first eluent, to thereby obtain a second eluent;
(i) processing the second eluent by diafiltration; and
(j) filtering the processed second eluent, thereby obtaining biologically active botulinum neurotoxin type A complex using a substantially APF chromatographic process, wherein the botulinum neurotoxin type A complex obtained has a potency of 2.0×107 to about 6.0×107 units/mg of botulinum neurotoxin type A complex.

### Claim 6 (depends on 5)

The process of claim 5, wherein the fermentation medium comprises no more than about 5% w/v of a vegetable-derived protein product, no more than about 2% w/v of a yeast extract and no more than about 2% w/v glucose, and wherein the pH level of the fermentation medium is from about pH 6.5 to about pH 8.0 at the commencement of the fermenting step.

### Claim 7 (depends on 5)

The process of claim 5, wherein the culturing step is carried out until the optical density of the culture medium at about 540 nm is between about 0.8 AU and about 4.5 AU.

### Claim 8 (depends on 5)

The process of claim 5, wherein the fermenting step is carried out for about 60 to 80 hours and until an optical density of the fermentation medium at about 890 nm decreases to between about 0.05 AU to about 0.7 AU.

### Claim 9 (depends on 5)

The process of claim 5, wherein the culturing step is initiated by introducing a Clostridium botulinum APF working cell bank content to the culture medium, wherein the working cell bank comprises at least about 1×104 to 5×107 colony-forming units of Clostridium botulinum per milliliter of the working cell bank, and wherein the Clostridium botulinum bacterium in the working cell bank have a substantially uniform morphology.

### Claim 10 (depends on 5)

The process of claim 5, wherein the botulinum neurotoxin obtained comprises one ng or less than one ng of residual nucleic acid for each mg of the botulinum neurotoxin obtained.

### Claim 11 (depends on 5)

The process of claim 5, wherein the process is carried out in one week or less.

### Claim 12

An APF chromatographic process for obtaining a biologically active botulinum neurotoxin, comprising the following sequential steps of:
(a) adding Clostridium botulinum bacteria from an APF working cell bank to an APF culture medium;
(b) culturing the Clostridium botulinum bacteria in the culture medium;
(c) fermenting the Clostridium botulinum bacteria from step (b) in an APF fermentation medium until Clostridium botulinum cell lysis occurs;
(d) harvesting the fermentation culture to provide a harvested fermentation medium;
(e) subjecting the harvested fermentation medium to concentration by filtration;
(f) diluting the filtered fermentation medium by addition of a buffer to obtain a diluted fermentation medium;
(g) a first contacting step in which the diluted fermentation medium is contacted with a capture chromatography, wherein the capture chromatography media is an anion exchange media;
(h) a second contacting step wherein an eluent from the first contacting step is contacted with a polishing chromatography media, wherein the polishing chromatography media is a cation exchange media, and
(i) filtering eluent from the second contacting step, thereby obtaining biologically active botulinum neurotoxin by the improved APF process, wherein the botulinum neurotoxin obtained comprises one ng or less than one ng of residual nucleic acid for each mg of the botulinum neurotoxin obtained and the process is carried out in one week or less.
